Doxorubicin

"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.

Descriptor ID	D004317
MeSH Number(s)	D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
Concept/Terms	Doxorubicin Doxorubicin Farmiblastina Farmiblastina Ribodoxo Ribodoxo Rubex Rubex Adriamycin Adriamycin Adriblastin Adriblastin Adriblastine Adriblastina Adriablastine Adriablastin Adrimedac Adrimedac DOXO-cell DOXO-cell DOXO cell Urokit Doxo-cell Urokit Doxo cell Doxolem Doxolem Doxorubicin Hexal Doxorubicin Hexal Doxorubicin Hydrochloride Doxorubicin Hydrochloride Hydrochloride, Doxorubicin Doxorubicin NC Doxorubicin NC Doxorubicina Ferrer Farm Doxorubicina Ferrer Farm Doxorubicina Funk Doxorubicina Funk Doxorubicina Tedec Doxorubicina Tedec Doxorubicine Baxter Doxorubicine Baxter Doxotec Doxotec Myocet Myocet Onkodox Onkodox

Below are MeSH descriptors whose meaning is more general than "Doxorubicin".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Polycyclic Aromatic Hydrocarbons [D02.455.426.559.847]
Naphthacenes [D02.455.426.559.847.562]
Anthracyclines [D02.455.426.559.847.562.050]
Daunorubicin [D02.455.426.559.847.562.050.200]
Doxorubicin [D02.455.426.559.847.562.050.200.175]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Naphthacenes [D04.615.562]
Anthracyclines [D04.615.562.050]
Daunorubicin [D04.615.562.050.200]
Doxorubicin [D04.615.562.050.200.175]
Carbohydrates [D09]
Glycosides [D09.408]
Aminoglycosides [D09.408.051]
Anthracyclines [D09.408.051.059]
Daunorubicin [D09.408.051.059.200]
Doxorubicin [D09.408.051.059.200.175]

Below are MeSH descriptors whose meaning is related to "Doxorubicin".

Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".

Doxorubicin
Epirubicin

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.

Bar chart showing 77 publications over 22 distinct years, with a maximum of 9 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2003	1	1	2
2004	1	2	3
2005	2	0	2
2006	2	3	5
2007	2	3	5
2008	0	1	1
2009	0	3	3
2010	6	3	9
2011	1	1	2
2012	2	2	4
2013	3	1	4
2014	0	4	4
2015	2	2	4
2016	2	0	2
2017	1	4	5
2018	3	1	4
2019	0	2	2
2020	1	2	3
2022	0	6	6
2023	0	1	1
2025	3	2	5

Below are the most recent publications written about "Doxorubicin" by people in Profiles.

Choppadandi M, Parmar K, Ghosh S, K SR, Rao KH, Singh AA, Sharma P, Kumar H, Turubilli HL, Chauhan SC, Yallapu MM, Kapusetti G. Self-Regulated Cobalt-Zinc-Ferrite Nanoprobe for Targeted Chemomagnetic Hyperthermia in Cancer Therapy. ACS Appl Mater Interfaces. 2025 Dec 31; 17(52):70454-70467.

View in: PubMed
Zhao M, Ma Z, Parris AB, Yang X. LSR overexpression induces chemoresistance in triple negative breast cancer cells through MDR1 upregulation and apoptosis attenuation. PLoS One. 2025; 20(11):e0336124.

View in: PubMed
Aare M, Padakanti SC, Singh M. In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts. AAPS PharmSciTech. 2025 Sep 11; 26(7):227.

View in: PubMed
Mondal T, Sahoo P, Nandi SK, Kundu S, Li M, Haldar N, Kabir R, Mitra K, Roy S, Das M, Ghosh CK. Opto-magnetic optimization enhances the multimodal therapeutic and diagnostic (UCL/T1-T2W MRI) potential of GdOF against MDA-MB-231. J Mater Chem B. 2025 Aug 13; 13(32):9993-10008.

View in: PubMed
Aare M, Lazarte JMS, Muthu M, Rishi AK, Singh M. Genetically bio-engineered PD-L1 targeted exosomes for immunotherapy of resistant triple negative breast cancer. Drug Deliv Transl Res. 2026 Feb; 16(2):693-710.

View in: PubMed
Chakrabarti S, Wagh C, Bagnall-Moreau C, Uddin F, Reiser J, Salas-Ramirez K, Ahles T, Hubbard K. Chemotherapy treatment alters DNA methylation patterns in the prefrontal cortex of female rat brain. Sci Rep. 2025 Jul 01; 15(1):20681.

View in: PubMed
Le KV, Nguyen HT, Pham PQ, Nguyen NH, Doan TLH, Nguyen LHT, Phan BT, Nguyen LTM, Park S, Pham NK, Krisbiantoro PA, Wu KC, Mai NXD. Biogenic fluorescent carbon dot-decorated mesoporous organosilica nanoparticles for enhanced bioimaging and chemotherapy. Nanoscale Horiz. 2025 Apr 22; 10(5):1000-1006.

View in: PubMed
Dhawan U, Tseng CL, Wu PH, Liao MY, Wang HY, Wu KC, Chung RJ. Theranostic doxorubicin encapsulated FeAu alloy@metal-organic framework nanostructures enable magnetic hyperthermia and medical imaging in oral carcinoma. Nanomedicine. 2023 02; 48:102652.

View in: PubMed
Kalvala AK, Nimma R, Bagde A, Surapaneni SK, Patel N, Arthur P, Sun L, Singh R, Kommineni N, Nathani A, Li Y, Singh M. The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice. Biochimie. 2023 May; 208:19-30.

View in: PubMed
Cobb MS, Tao S, Shortt K, Girgis M, Hauptman J, Schriewer J, Chin Z, Dorfman E, Campbell K, Heruth DP, Shohet RV, Dawn B, Konorev EA. Smad3 promotes adverse cardiovascular remodeling and dysfunction in doxorubicin-treated hearts. Am J Physiol Heart Circ Physiol. 2022 12 01; 323(6):H1091-H1107.

View in: PubMed

People

Explore

Similar Concepts

Top Journals